Clinical Review
Monitoring Lipids in Patients Treated With Ziprasidone or Aripiprazole
Consensus Guidelines
Fed Pract. 2010 November;27(11):35
Author and Disclosure Information
Shaiza Khan, PharmD; and Jennifer Zacher, PharmD, BCPP
Dr. Khan and Dr. Zacher are clinical pharmacy specialists at the North Chicago VA Medical Center in Illinois.
Despite a consensus that lipids should be monitored in all patients treated with a second-generation antipsychotic, lipid monitoring is inconsistent for patients receiving ziprasidone or aripiprazole. Here's why, and how an investigation at one VA medical center prompted practice recommendations.